

Agenda March 22, 2012 | 8AM-6PM Goldberg Auditorium, Moores Cancer Center

Organizers:

- Thomas Kipps, MD, PhD, Director, Moores Cancer Center
- Ida Deichaite, PhD, Director, Industry Relations, Moores Cancer Center

Symposium Chair:

David Cheresh, PhD, Associate Director for Translational Research and Professor of Pathology, Moores Cancer Center

Symposium Co-Chair:

Catriona Jamieson, MD, PhD, Director, Stem Cell Research Program, Associate Professor of Medicine, Moores Cancer Center

8:15AM	Registration and Continental Breakfast
8:45AM	Welcome and Overview
	David Brenner, MD, UC San Diego School of Medicine
	Thomas Kipps, MD, PhD, Moores Cancer Center
9:00AM	<ul> <li>Armed with Genomics, Is the Target in Sight for Myelodysplastic Syndromes?</li> <li>Azra Raza, MD, MDS Center, Columbia University Medical Center</li> </ul>
9:20AM	Session: Cilengitide, a New Therapeutic for Brain Cancer, from Bench to Bedside and Back
	Cilengitide, from Discovery to Clinical Development and Back     David Cheresh, PhD, Moores Cancer Center
	<ul> <li>Targeting for Glioblastoma Patients with Cilengitide: Promises and Challenges</li> <li>David Reardon, MD, Center for Neuro-Oncology, Dana-Farber Cancer Institute</li> </ul>
10:15AM	Break
10:30AM	Session: Successful Industry Academia Collaboration
	Malignant Progenitor Re-Programming     Catriona Jamieson, MD, PhD, Moores Cancer Center
	Lessons Learned from Clinic     Wendy Levin, MD, MS, Pfizer



11:30AM	Keynote Presentation
	<ul> <li>Stem Cells and Cancer</li> <li>Irving Weissman, MD, Stanford School of Medicine</li> </ul>
12:00PM	Lunch
1:15PM	Session: First in Class Cancer Drug Pipeline
	<ul> <li>PAK Inhibitors for Cancer – Trailblazing a Path to the Clinic David Campbell, PhD, Afraxis</li> </ul>
	<ul> <li>Targeting Pim Kinases in Hematological Malignancies</li> <li>Erika Keeton, PhD, AstraZeneca Pharmaceuticals</li> </ul>
	<ul> <li>The Mouse that ROR'ed – Targeting Onco-Embryonic Antigens</li> <li>Thomas Kipps, MD, PhD, Moores Cancer Center</li> </ul>
	<ul> <li>From Phenotypic Screen to a Druggable Node in the Wnt Pathway</li> <li>Martin Seidel, PhD, Genomics Institute of the Novartis Research Foundation</li> </ul>
2:40PM	<ul> <li>Understanding Rejection (How and Why) through the Melanoma Model Francesco Marincola, MD, National Institutes of Health</li> </ul>
3:00PM	<ul> <li>The Challenge of a Biosimilar Development</li> <li>Udo Müller, MD, PhD, Teva Pharmaceuticals</li> </ul>
3:25PM	Break
3:40PM	<ul> <li>The New Center for Innovative Therapies: A University-Industry Partnership to Discover and Develop New Treatments and Cures</li> <li>Marye Anne Fox, PhD, Chancellor, University of California San Diego</li> <li>Thomas Kipps, MD, PhD, Moores Cancer Center</li> </ul>
4:00PM	Panel Discussion: Discovery to TherapiesIt's Changing and Quickly



- Moderator: Duane Roth, CONNECT
- Robert Abraham, PhD, Pfizer
- Sandra Brown, PhD, University of California San Diego
- Dennis Carson, MD, Moores Cancer Center
- David Kabakoff, PhD, Sofinnova Ventures
- Jonathan Thomas, PhD, JD, CIRM
- Carl Weissman, Accelerator

Symposium Reception

5:00PM